Supplemental material
Journal of Medical Economics
Volume 23, 2020 - Issue 11
Open access
2,791
Views
7
CrossRef citations to date
0
Altmetric
Diabetes
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective
Johan Jendlea Institute of Medical Sciences, Örebro University, Örebro, SwedenCorrespondence[email protected]
https://orcid.org/0000-0003-1025-1682
, https://orcid.org/0000-0003-1025-1682
Åsa Ericssonb Novo Nordisk Scandinavia AB, Malmö, Sweden
, Bertil Ekmanc Department of Endocrinology, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Swedenhttps://orcid.org/0000-0001-8732-7361
, Stefan Sjöbergd Department of Medicine, Karolinska Huddinge University Hospital, Stockholm, Sweden
, Jens Gundgaarde Novo Nordisk A/S, Søborg, Denmark
, João da Rocha Fernandese Novo Nordisk A/S, Søborg, Denmark
, Ann-Charlotte Mårdbyb Novo Nordisk Scandinavia AB, Malmö, Swedenhttps://orcid.org/0000-0003-0579-3583
, Barnaby Huntf Ossian Health Economics and Communications, Basel, Switzerlandhttps://orcid.org/0000-0001-5420-279X
, Samuel J. P. Malkinf Ossian Health Economics and Communications, Basel, Switzerlandhttps://orcid.org/0000-0003-1306-7784
& Maria Thunanderf Department of Clinical Sciences, Endocrinology and Diabetes, Lund University, Lund, Swedenhttps://orcid.org/0000-0001-6888-1295
show all
Pages 1311-1320
|
Received 24 Apr 2020, Accepted 27 Jul 2020, Published online: 14 Sep 2020
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.